Welcome to LookChem.com Sign In|Join Free
  • or
1,1-dimethylethyl 4-(3-hydroxy-2-methylphenyl)piperazine-1-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

871339-60-5

Post Buying Request

871339-60-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

871339-60-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 871339-60-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,3,3 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 871339-60:
(8*8)+(7*7)+(6*1)+(5*3)+(4*3)+(3*9)+(2*6)+(1*0)=185
185 % 10 = 5
So 871339-60-5 is a valid CAS Registry Number.

871339-60-5Relevant academic research and scientific papers

Synthesis and SAR of tolylamine 5-HT6 antagonists

Singer, Jamie M.,Wilson, Michael W.,Johnson, Paul D.,Graham, Shelley R.,Cooke, Leonard W.,Roof, Robin L.,Boxer, Peter A.,Gold, Lisa H.,Meltzer, Leonard T.,Janssen, Ann,Roush, Nicole,Campbell, Jeffrey E.,Su, Ti-Zhi,Hurst, Susan I.,Stoner, Chad L.,Schwarz, Jacob B.

scheme or table, p. 2409 - 2412 (2009/12/25)

The synthesis and SAR of tolylamines with 5-HT6 receptor antagonist activity is presented. The amine, core aromatic, peripheral aromatic, and ether linker moieties of HTS hit 1 were modulated and the effect on potency at 5-HT6 examin

KINASE MODULATORS AND METHODS OF USE

-

Page/Page column 120, (2010/02/15)

The present invention relates to compounds of the Formula I and II wherein R, R21, R25-R33, m, n, X21-X23, and Q1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 871339-60-5